Session brief description: Cerevel Therapeutics is advancing a broad and diverse neuroscience pipeline of small molecule therapies to address significant unmet medical needs and limited treatment options for patients suffering from some of the most prevalent neuroscience diseases. Dr. Takahashi will give an overview of our clinical pipeline comprised of multiple therapeutic candidates that have the potential to achieve optimal therapeutic activity while minimizing the unintended side effects of currently available therapies.
Chair(s) name (if applicable): N/A
Speaker(s) name, with institution name and country: Koji Takahashi, PhD. Sr. Director Medical Affairs, Cerevel Therapeutics, USA.
Stay tuned for more information on upcoming Congresses hosted by the International College of Neuropsychopharmacology (CINP).